Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC).

Next Previous
X
Search
Trial Profile

Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Jun 2016 Status changed from recruiting to completed, according to results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 27 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top